Broader vessel formats, native CDS control, and 50% greater collection capacity over the WFC III help drug discovery labs scale without a platform swap.
The updated requirements clarify what pharmaceutical operations must retain and establish strict conditions for using digital records instead of physical samples
How terminal cycle validation for injectable drug products works, from heat distribution studies and F₀ calculations to parametric release and requalification requirements
How pharmaceutical manufacturers use nitrogen blanketing and high-purity gas generators to protect drug products from oxidation and moisture-driven degradation